Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial-Reference-Cited by-同舟云学术

Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial

Published:2022-10 Issue: Volume:239 Page:109604
ISSN:0376-8716
Container-title:Drug and Alcohol Dependence
language:en
Short-container-title:Drug and Alcohol Dependence

Author:

McAnulty Christina,Bastien Gabriel,Eugenia Socias M.,Bruneau Julie,Foll Bernard Le,Lim Ron,Brissette Suzanne,Ledjiar Omar,Marsan Stephanie,Talbot Annie,Jutras-Aswad Didier

Publisher

Elsevier BV

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Toxicology

Reference27 articles.

1. Diagnostic and statistical manual of mental disorders: DSM-5;American Psychiatric Association,2013

2. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis;Bahji;Acta Psychiatr. Scand.,2019

3. “I wanted something that was more flexible”: a qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program;Checkley;Subst. Abus,2022

4. CRISM National Guideline Review Committee, 2018. CRISM National Guideline for the Clinical Management of Opioid Use Disorder.

5. Metabolic and addiction indices in patients on opioid agonist medication-assisted treatment: a comparison of buprenorphine and methadone;Elman;Sci. Rep.,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of take-home methadone treatment among patients with opioid use disorders during COVID-19: A systematic review;Health Sciences Review;2024-09

2. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial;Addictive Behaviors;2024-07

3. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study;The Canadian Journal of Psychiatry;2023-10-30

4. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs;Substance Abuse Treatment, Prevention, and Policy;2023-05-22

5. Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada;Quality of Life Research;2023-04-07